Long‐term efficacy and safety of alemtuzumab in advanced primary cutaneous T‐cell lymphomas. (March 2014)

• Record Type: Journal Article
• Authors: de, A.; Guitera, P.; Brice, P.; Moulonguet, I.; Mouly, F.; Bouaziz, J.‐D.; Battistella, M.; Madelaine, I.; Roux, J.; Ram‐Wolff, C.; Cayuela, J.‐M.; Bachelez, H.; Bensussan, A.; Michel, L.; Bagot, M.
• Is Part Of: British journal of dermatology. Volume 170:Number 3(2014:Mar.)
• Page Start: 720
• Page End: 724
• Publication Date: 2014-03
• Subjects: Dermatology -- Periodicals; Skin -- Diseases -- Periodicals; 616.5
• DOI: 10.1111/bjd.12690
• Languages: English
• ISSNs: 0007-0963

Abstract

<abstract abstract-type="short" xml:lang="en" id="bjd12690-abs-0002"> <title> <x xml:space="preserve">Abstract</x> </title> <p> <bold>What's already known about this topic?</bold> </p> <p> <list id="bjd12690-list-0001" list-type="bullet"> <list-item> <p>Alemtuzumab has shown short‐term efficacy in small numbers of patients with advanced primary cutaneous T‐cell lymphomas.</p> </list-item> </list> </p> <p> <bold>What does this study add?</bold> </p> <p> <list id="bjd12690-list-0002" list-type="bullet"> <list-item> <p>Alemtuzumab may induce long‐term remission (&gt; 2 years) in patients with Sézary syndrome.</p> </list-item> <list-item> <p>Alemtuzumab is poorly effective in nontransformed mycosis fungoides and transformed CTCL.</p> </list-item> </list> </p> </abstract>